NODE 0 mRS 0: 13.6% (n=551) mRS 1: 19.4% (n=785) mRS 2: 14.7% (n=597) mRS 3: 16.5% (n=668) mRS 4: 21.1% (n=855) mRS 5: 7.0% (n=324) mRS 6: 6.7% (n=271)

Slides:

Advertisements

Similar presentations

Governance of a Stroke Thrombolysis Service

Advertisements

Thrombolysis for stroke in older people.

Insert A tree starts with the dummy node D D 200 D 7 Insert D

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,

T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr.

CONSEQUENCES WHAT DOES THE WORD MEAN TO YOU?. ARE ALL CONSEQUENCES NEGATIVE?

Stroke,Past,Present, Future. Impact of stroke 1,2 Stroke has a major impact on people’s lives Stroke is the: –single most devastating effect of hypertension.

CARDIOVASCULAR DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.

Congestive Heart Failure!!. Question 1 What’s a symptom of congestive heart failure?? A. shortness of breath B. chest pain C. No appetite D. all of the.

Using stroke scales to assess the patient – Rankin and NIHSS

Severity assessment for lower respiratory tract infections: potential use and validity of CRB-65 in primary care N. Francis, J. Cals, C. Butler, K. Hood,

Curaçao Stroke Questionnaire Izzy Gerstenbluth Norédiz Lourents November 12, 2010.

Peter Emery, MD Specialist in Clinical Hypertension InterMed Portland, ME.

Are you at Risk for a Stroke, Aneurysm or Peripheral Arterial Disease?

 Alcohol thins your blood so less blood clots  Alcohol also helps with stress.

Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.

The Stroke Oxygen Supplementation PILOT Study C. Roffe, K.Ali, A. Warusevitane, S. Sills, S. Pountain, P Jones, R Gray, P. Crome North Staffordshire Combined.

PROTECT Progesterone for Traumatic brain injury. What was the PROTECT study? Multicenter Moderate to severe trauma to the brain Patients enrolled within.

Linear Regression What kind of correlation would the following scatter plots have? Negative Correlation Positive Correlation No Correlation.

Dual sensory loss: Its significance and importance for those working with older people Sue Brown, Sense.

Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,

Cardiovascular Disease Prevention Know, Understand, and Act University of Ottawa Heart Institute Division of Prevention & Rehabilitation.

Long-Term Outcomes after Acute Stroke Treatment Larry B. Goldstein, M.D. Professor of Medicine (Neurology) Center for Cerebrovascular Disease Center for.

Humaid Dherar Belhoul Grade 8 AB May  “Blood pressure” is the force of blood pushing against the walls of the arteries as the heart pumps out blood.

December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages

Sanaz Sakiani, MD Endocrinology Fellow Journal Club

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Levels of Neuropeptide Proenkephalin.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risk Stratification for In-Hospital Mortality in.

+ Take Charge of Your Health Health for Hearts United Leadership Institute Cyneetha Strong, MD May 31, 2014.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Date of download: 11/13/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Reality of Heart Failure in Latin America J.

Keystone Heart Reflect Neurology

From: A Randomized Trial Comparing Acupuncture, Simulated Acupuncture, and Usual Care for Chronic Low Back Pain Arch Intern Med. 2009;169(9): doi: /archinternmed

Copyright © 2009 American Medical Association. All rights reserved.

From: Intra-arterial Prourokinase for Acute Ischemic StrokeThe PROACT II Study: A Randomized Controlled Trial JAMA. 1999;282(21): doi: /jama

Copyright © 2015 American Medical Association. All rights reserved.

Volume 386, Issue 9988, Pages (July 2015)

Copyright © 2005 American Medical Association. All rights reserved.

Association between Systolic Blood Pressure

Copyright © 2010 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.

Date of download: 1/13/2018 Copyright © ASME. All rights reserved.

Predictors of Good Outcome After Stent-Retriever Thrombectomy in Acute Basilar Artery Occlusion by Woong Yoon, Seul Kee Kim, Tae Wook Heo, Byung Hyun Baek,

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Prestroke Glycemic Control Is Associated With the Functional Outcome in Acute Ischemic Stroke by Masahiro Kamouchi, Takayuki Matsuki, Jun Hata, Takahiro.

Low Pulse Pressure After Acute Ischemic Stroke is Associated With Unfavorable Outcomes: The Taiwan Stroke Registry by Sung‐Chun Tang, Jiu‐Haw Yin, Chung‐Hsiang.

Prevalence and Significance of Unrecognized Renal Dysfunction in Patients with Stroke David Pereg, MD, Zach Rozenbaum, MD, Dina Vorobeichik, MA, Nir Shlomo,

Figure 2 Medial occipital lobe (designated by visual cortical brain regions) hypometabolism in anti–NMDA receptor encephalitis Medial occipital lobe (designated.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

دانشگاه علوم پزشکی بوشهر دانشکده بهداشت

دانشگاه علوم پزشکی بوشهر دانشکده بهداشت

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial

Modified Rankin Scale (mRS) scores were evaluated as a measure of neurological outcome function of participants from 30 to 180 days after stoke. Modified.

Volume 385, Issue 9968, Pages (February 2015)

Figure Alluvial plot of modified Rankin Scale (mRS) scores during and at the end of hospital stay Alluvial plot of modified Rankin Scale (mRS) scores during.

Three outcome measures from the NINDS tPA trial

Modified Rankin Scale (mRS) scores were evaluated as a measure of neurological outcome function of participants from 30 to 180 days after stoke. Modified.

The outcome difference in patients with spontaneous intracerebral hematoma ID23049 Author: Zanda Lāse 1,dr.med. Juris Dzenis2,3, dr. Ilga Ķikule1,4 1Faculty.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

(A) ROC for the prediction of 5-year mortality in unoperated significant MR. AUCs and corresponding p values are shown for lateral annulus E/E′ (AUC=0.69,

Predictive value of the National Institutes of Health Stroke Scale and the Mini-Mental State Examination for neurologic outcome after coronary artery.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Figure Clinical course and CSF/serum NMDA receptor (NMDAR) antibody (ab) titers of mother and infant Titers were measured with immunohistochemistry of.

Trend of mean arterial blood pressure over time stratified by outcome defined by modified Rankin Scale (mRS) score: good outcome defined as mRS score ≤2;

Differences in time remaining independent in activities of daily living (ADL) assessed by the modified Rankin scale between patients with pure autonomic.

Presentation transcript:

NODE 0 mRS 0: 13.6% (n=551) mRS 1: 19.4% (n=785) mRS 2: 14.7% (n=597) mRS 3: 16.5% (n=668) mRS 4: 21.1% (n=855) mRS 5: 7.0% (n=324) mRS 6: 6.7% (n=271) NODE 1 mRS 0: 24.6% (n=549) mRS 1: 33.8% (n=753) mRS 2: 23.4% (n=521) mRS 3: 14.1% (n=315) mRS 4: 2.7% (n=61) mRS 5: 0.3% (n=7) mRS 6: 1.1% (n=25) NODE 2 mRS 0: 0.1% (n=2) mRS 1: 1.8% (n=32) mRS 2: 4.2% (n=76) mRS 3: 19.4% (n=353) mRS 4: 43.6% (n=794) mRS 5: 17.4% (n=317) mRS 6: 13.5% (n=246) NODE 3 mRS 0: 46.3% (n=500) mRS 1: 44.9% (n=484) mRS 2: 5.6% (n=60) mRS 3: 1.3% (n=14) mRS 4: 0.7% (n=7) mRS 5: 0.1% (n=1) mRS 6: 1.2% (n=13) NODE 4 mRS 0: 4.3% (n=49) mRS 1: 23.4% (n=269) mRS 2: 40.0% (n=461) mRS 3: 26.1% (n=301) mRS 4: 4.7% (n=54) mRS 5: 0.5% (n=6) mRS 6: 1.0% (n=12) NODE 5 mRS 0: 0.2% (n=2) mRS 1: 2.5% (n=29) mRS 2: 6.3% (n=73) mRS 3: 28.8% (n=334) mRS 4: 52.7% (n=612) mRS 5: 4.0% (n=58) mRS 6: 4.6% (n=53) NODE 6 mRS 0: 0.0% (n=0) mRS 1: 0.5% (n=3) mRS 2: 0.5% (n=3) mRS 3: 2.9% (n=19) mRS 4: 27.6% (n=182) mRS 5: 39.3% (n=259) mRS 6: 29.3% (n=193) NODE 7 mRS 0: 78.3% (n=349) mRS 1: 17.7% (n=79) mRS 2: 2.7% (n=12) mRS 3: 0.2% (n=1) mRS 4: 0.2% (n=1) mRS 5: 0.0% (n=0) mRS 6: 0.9% (n=4) NODE 8 mRS 0: 23.9% (n=151) mRS 1: 63.9% (n=405) mRS 2: 7.6% (n=48) mRS 3: 2.1% (n=13) mRS 4: 0.9% (n=6) mRS 5: 0.2% (n=1) mRS 6: 1.4% (n=9) NODE 9 mRS 0: 0.0% (n=0) mRS 1: 2.8% (n=15) mRS 2: 8.3% (n=44) mRS 3: 37.5% (n=200) mRS 4: 46.7% (n=249) mRS 5: 2.4% (n=13) mRS 6: 2.3% (n=12) NODE 10 mRS 0: 0.3% (n=2) mRS 1: 2.2% (n=14) mRS 2: 4.6% (n=29) mRS 3: 21.3% (n=134) mRS 4: 57.8% (n=363) mRS 5: 7.2% (n=45) mRS 6: 6.5% (n=41) NODE 11 mRS 0: 0.0% (n=0) mRS 1: 0.7% (n=3) mRS 2: 0.5% (n=2) mRS 3: 1.6% (n=7) mRS 4: 22.6% (n=101) mRS 5: 37.4% (n=167) mRS 6: 37.4% (n=167) NODE 12 mRS 0: 0.0% (n=0) mRS 1: 0.0% (n=0) mRS 2: 0.5% (n=1) mRS 3: 5.7% (n=12) mRS 4: 38.2% (n=81) mRS 5: 43.4% (n=92) mRS 6: 12.3% (n=26) NODE 13 mRS 0: 0.0% (n=0) mRS 1: 3.9% (n=11) mRS 2: 11.5% (n=32) mRS 3: 44.1% (n=123) mRS 4: 36.2% (n=101) mRS 5: 2.2% (n=6) mRS 6: 2.2% (n=6) NODE 14 mRS 0: 0.0% (n=0) mRS 1: 1.6% (n=4) mRS 2: 4.7% (n=12) mRS 3: 30.3% (n=77) mRS 4: 58.3% (n=148) mRS 5: 2.8% (n=7) mRS 6: 2.4% (n=6) NODE 15 mRS 0: 0.0% (n=0) mRS 1: 0.0% (n=0) mRS 2: 0.75% (n=1) mRS 3: 0.75% (n=1) mRS 4: 17.3% (n=23) mRS 5: 27.8% (n=37) mRS 6: 53.4% (n=71) NODE 16 mRS 0: 0.0% (n=0) mRS 1: 0.9% (n=3) mRS 2: 0.3% (n=1) mRS 3: 1.9% (n=6) mRS 4: 24.8% (n=78) mRS 5: 41.4% (n=130) mRS 6: 30.6% (n=96) B-NIHSSS ≤ 14.5 B-NIHSSS > 14.5CHF: YesCHF: No Day-30 mRS ≤ 0Day-30 mR S> 0Age ≤ 70.5 years Age >70.5 years Day-30 mRS ≤ 1Day-30 mRS > 1Day-30 mRS ≤ 4Day-30 mRS > 4 Thrombolytic: No Thrombolytic: Yes Day-30 mRS ≤ 3 Day-30 mRS > 3 DAY-90 mRS Figure e-1. Title: Ordinal tree model for predicting day-90 stroke outcome by modified Rankin Scale score (mRS) (n=4051). Legend: Each tree node contains day-90 mRS values: mRS of 0 = no symptoms; mRS of 1 = no significant disability; mRS of 2 = Slight disability; mRS of 3 = moderate disability; mRS of 4 = moderately severe disability; mRS of 5 = severe disability; mRS of 6 = death; B-NIHSSS=Baseline National Institutes of Health Scale score; B-SBP=Baseline systolic blood pressure; CHF=congestive heart failure